Evaluation of Rare Insulin-derived Amyloidoma With 18 F-FDG PET/CT.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40768197.
- Also identified by DOI 10.1097/RLU.0000000000006075 and PMC identifier 13132038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amyloidosis causes extracellular tissue deposition of insoluble polymeric protein fibrils. Insulin-derived amyloidosis (AIns) is a rare complication of insulin therapy, causing insulin accumulation at the repeated injection site, forming subcutaneous lumps. This causes impaired insulin absorption, affecting further glycemic management. Our patient had anterior abdominal soft tissue lesions and a biopsy concerning multiple myeloma. 18 F-FDG PET/CT done to evaluate any osseous/other extraosseous lesions demonstrated hypermetabolic lesions confined to the anterior abdomen. The mass was excised, and histopathology revealed insulin-derived amyloidoma. Per the literature search, only 1 previous case of AIns has been evaluated with PET/CT. PET/CT helps assess disease extent, localize, guide biopsy, and follow-up.
Medical subject headings
- Fluorodeoxyglucose F18
- Positron Emission Tomography Computed Tomography
- Amyloidosis
- Insulin